Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S. Human Pharma. His arrival comes at a ...

Boehringer plans to submit for FDA and other global approvals in both indications. Boehringer Ingelheim recorded a second straight Phase III win Monday for its drug nerandomilast, which met the ...

NEW YORK – Boehringer Ingelheim on Wednesday said the US Food and Drug Administration accepted its new drug application for the irreversible tyrosine kinase inhibitor zongertinib as a treatment for ...

Plus, news about Madrona and Ab­dera: Boehringer In­gel­heim com­bines two can­cer units: The drug­mak­er is merg­ing its can­cer vac­cine unit AMAL Ther­a­peu­tics … ...